PD 163070, a potent endothelin-A selective antagonist with long duration of action.

被引：0

作者：

Lee, C ^{[1
]}

Cheng, XM ^{[1
]}

Repine, J ^{[1
]}

Bradford, L ^{[1
]}

Reyner, E ^{[1
]}

Stewart, B ^{[1
]}

Hallak, H ^{[1
]}

Welch, KM ^{[1
]}

Walker, D ^{[1
]}

Haleen, S ^{[1
]}

Doherty, A ^{[1
]}

机构：

[1] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI 48105

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 1997年 / 213卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

引用

页码：195 / MEDI

页数：1

共 50 条

[31] Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist
Liu, Yun
Wang, Wei
Qian, Hongjie
Gui, Yuzhou
Wang, Yating
Song, Rong
Chen, Qian
Rowinsky, Eric
Wang, Sheng
Liang, Xiaoguang
Gu, Kaicun
Zhou, Bo
Zhang, Weiwei
Zhang, Liqin
Yu, Chen
Jia, Jingying
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (03):
[32] Effect of Ro 61-1790, a selective endothelin-A receptor antagonist, on systemic and uterine hemodynamics and fetal oxygenation in sheep
McElvy, S
Greenberg, S
Baker, RS
Khoury, J
Clark, KE
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (01) : 55 - 60
[33] Pulmonary vasoreactivity in rats with heart failure following myocardial infarction: effect of long-term oral therapy with the selective endothelin-A receptor antagonist LU 135252
Bauersachs, J
Hu, K
Ertl, G
Koch, TH
Hagebeuker, A
Konrad, C
Schmeck, J
EUROPEAN HEART JOURNAL, 2000, 21 : 596 - 596
[34] The selective endothelin-A-receptor antagonist LU 135.252 inhibits the direct arrhythmogenic action of endothelin-1
Merkely, B
Szabó, T
Gellér, L
Kiss, O
Horkay, F
Raschack, M
Juhász-Nagy, A
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 36 : S314 - S316
[35] STRUCTURE-ACTIVITY-RELATIONSHIPS OF THE POTENT COMBINED ENDOTHELIN-A ENDOTHELIN-B RECEPTOR ANTAGONIST AC-DDIP(16)-LEU-ASP-ILE-ILE-TRP(21) - DEVELOPMENT OF ENDOTHELIN-B RECEPTOR-SELECTIVE ANTAGONISTS
CODY, WL
HE, JX
DEPUE, PL
WAITE, LA
LEONARD, DM
SEFLER, AM
KALTENBRONN, JS
HALEEN, SJ
WALKER, DM
FLYNN, MA
WELCH, KM
REYNOLDS, EE
DOHERTY, AM
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (15) : 2809 - 2819
[36] AHR-6646, A NEW, POTENT NEUROLEPTIC WITH A LONG DURATION OF ACTION
JOHNSON, DN
TURLEY, BC
COFFIN, CB
JONES, MR
FUNDERBURK, WH
FEDERATION PROCEEDINGS, 1978, 37 (03) : 480 - 480
[37] Oral sitaxsentan, an endothelin-A selective receptor antagonist, reduces systemic blood pressure in patients with mild-to-moderate primary hypertension
Calhoun, DA
Renfroe, K
Alper, AB
CIRCULATION, 2000, 102 (18) : 417 - 417
[38] BIOCHEMICAL AND PHARMACOLOGICAL PROFILE OF A POTENT AND SELECTIVE ENDOTHELIN B-RECEPTOR ANTAGONIST, BQ-788
ISHIKAWA, K
IHARA, M
NOGUCHI, K
MASE, T
MINO, N
SAEKI, T
FUKURODA, T
FUKAMI, T
OZAKI, S
NAGASE, T
NISHIKIBE, M
YANO, M
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) : 4892 - 4896
[39] Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg(16)-Leu-Asp-Ile-[NMe]Ile-Trp(21) (PD 156252): Examination of its pharmacokinetic and spectral properties
Cody, WL
He, JX
Reily, MD
Haleen, SJ
Walker, DM
Reyner, EL
Stewart, BH
Doherty, AM
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (14) : 2228 - 2240
[40] PD156707: A potent antagonist of endothelin-1 in human diseased coronary arteries and vein grafts
Maguire, JJ
Davenport, AP
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 : S239 - S240

← 1 2 3 4 5 →